William Ransom & Son plc ("Ransom"), announces today that it has received notification from the regulator, the Medicines and Healthcare products Regulatory Agency ("MHRA"), of the grant of a Marketing Authorisation for Alateris, the glucosamine product for the prescription market to which Ransom secured exclusive UK rights under a 10 year agreement with Navamedic, signed in March 2007.  For the full announcement, click here.